A Phase I Study of SR-2508 and Cyclophosphamide Administered by Intravenous Injection

Howard Bailey; R. Timothy Mulcahy; Kendra D. Tutsch; Jack M. Rozental; Dona Alberti; Rhoda Z. Arzoomanian; Mary B. Tombes; Donald L. Trump; George Wilding

A Phase I Study of SR-2508 and Cyclophosphamide Administered by Intravenous Injection

Howard Bailey, R. Timothy Mulcahy, Kendra D. Tutsch, Jack M. Rozental, Dona Alberti, Rhoda Z. Arzoomanian, Mary B. Tombes, Donald L. Trump, George Wilding

Neurology

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

SR-2508, a less lipophilic and neurotoxic analogue of the nitroimidazole, misonidazole, has exhibited significant chemosensitization proper ties in preclinical studies with alkylating agents. A phase I trial was carried out to assess toxicity and possible pharmacological interactions of the combination of short infusions of SR-2508 and cyclophosphamide (CP). Patients were randomly assigned to receive either CP alone followed in 3 wk by CP + SR-2508, or CP + SR-2508 followed by CP alone. All additional courses were CP + SR-2508. The maximum tolerated dose of the combination was determined by dose escalation of SR-2508 while the dose of CP remained fixed, initially 1.0 u nr. and then a second maximum tolerated dose was determined with CP at 1.6 g/m2. One hundred seven teen Ã

Original language	English (US)
Pages (from-to)	1099-1104
Number of pages	6
Journal	Cancer Research
Volume	51
Issue number	4
State	Published - Feb 1991

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{05dab607e6854923bc7c1d0f4a11ef75,

title = "A Phase I Study of SR-2508 and Cyclophosphamide Administered by Intravenous Injection",

abstract = "SR-2508, a less lipophilic and neurotoxic analogue of the nitroimidazole, misonidazole, has exhibited significant chemosensitization proper ties in preclinical studies with alkylating agents. A phase I trial was carried out to assess toxicity and possible pharmacological interactions of the combination of short infusions of SR-2508 and cyclophosphamide (CP). Patients were randomly assigned to receive either CP alone followed in 3 wk by CP + SR-2508, or CP + SR-2508 followed by CP alone. All additional courses were CP + SR-2508. The maximum tolerated dose of the combination was determined by dose escalation of SR-2508 while the dose of CP remained fixed, initially 1.0 u nr. and then a second maximum tolerated dose was determined with CP at 1.6 g/m2. One hundred seven teen {\~A}",

author = "Howard Bailey and {Timothy Mulcahy}, R. and Tutsch, {Kendra D.} and Rozental, {Jack M.} and Dona Alberti and Arzoomanian, {Rhoda Z.} and Tombes, {Mary B.} and Trump, {Donald L.} and George Wilding",

year = "1991",

month = feb,

language = "English (US)",

volume = "51",

pages = "1099--1104",

journal = "Cancer Research",

issn = "0008-5472",

number = "4",

}

TY - JOUR

T1 - A Phase I Study of SR-2508 and Cyclophosphamide Administered by Intravenous Injection

AU - Bailey, Howard

AU - Timothy Mulcahy, R.

AU - Tutsch, Kendra D.

AU - Rozental, Jack M.

AU - Alberti, Dona

AU - Arzoomanian, Rhoda Z.

AU - Tombes, Mary B.

AU - Trump, Donald L.

AU - Wilding, George

PY - 1991/2

Y1 - 1991/2

N2 - SR-2508, a less lipophilic and neurotoxic analogue of the nitroimidazole, misonidazole, has exhibited significant chemosensitization proper ties in preclinical studies with alkylating agents. A phase I trial was carried out to assess toxicity and possible pharmacological interactions of the combination of short infusions of SR-2508 and cyclophosphamide (CP). Patients were randomly assigned to receive either CP alone followed in 3 wk by CP + SR-2508, or CP + SR-2508 followed by CP alone. All additional courses were CP + SR-2508. The maximum tolerated dose of the combination was determined by dose escalation of SR-2508 while the dose of CP remained fixed, initially 1.0 u nr. and then a second maximum tolerated dose was determined with CP at 1.6 g/m2. One hundred seven teen Ã

AB - SR-2508, a less lipophilic and neurotoxic analogue of the nitroimidazole, misonidazole, has exhibited significant chemosensitization proper ties in preclinical studies with alkylating agents. A phase I trial was carried out to assess toxicity and possible pharmacological interactions of the combination of short infusions of SR-2508 and cyclophosphamide (CP). Patients were randomly assigned to receive either CP alone followed in 3 wk by CP + SR-2508, or CP + SR-2508 followed by CP alone. All additional courses were CP + SR-2508. The maximum tolerated dose of the combination was determined by dose escalation of SR-2508 while the dose of CP remained fixed, initially 1.0 u nr. and then a second maximum tolerated dose was determined with CP at 1.6 g/m2. One hundred seven teen Ã

UR - http://www.scopus.com/inward/record.url?scp=0025863277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025863277&partnerID=8YFLogxK

M3 - Article

C2 - 1825475

AN - SCOPUS:0025863277

SN - 0008-5472

VL - 51

SP - 1099

EP - 1104

JO - Cancer Research

JF - Cancer Research

IS - 4

ER -

A Phase I Study of SR-2508 and Cyclophosphamide Administered by Intravenous Injection

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this